Fundraising Fox
CytoAgents
Pittsburgh, US · Founded 2018 · Delaware corporation · 4 known investors
Find your way into CytoAgents
Sign up to see every warm intro you have to CytoAgents
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CytoAgents team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.
Founders & leadership
Investors · 4
How we know: Boston Harbor Angels's portfolio page · Not right? Tell us
How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$13.1M disclosed across 2 of 3 rounds · 2020–2023
▶$7MraisedMay 2023 · 23 investors · Other Health CareRule 506(b)
- Roy PriebExecutive Officer
- Robert L FerrisDirector
- Stanley MarksDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- Catherine MottDirector
- Offering amount
- $15.2M
- Amount sold
- $7M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$6.1MraisedAug 2021 · 23 investors · Other Health CareRule 506(b)
- Catherine MottDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- John FriedmanDirector
- Stanley MarksDirector
- Offering amount
- $6.5M
- Amount sold
- $6.1M
- Minimum investment
- $10K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as CytoAgents.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does CytoAgents do?
- CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.
- Who are CytoAgents's investors?
- CytoAgents's investors include Boston Harbor Angels, Delaware Crossing Investor Group, Richard King Mellon Foundation.
- How much funding has CytoAgents raised?
- CytoAgents has disclosed $13.1M raised across 2 of its 3 known rounds.
- Where is CytoAgents headquartered?
- CytoAgents is headquartered in Pittsburgh, US.